Advertisement

HIV Conference Coverage

TheBodyPRO.com's Conference Coverage
CROI 2010

DRUGS IN DEVELOPMENT: CROI 2010 Wrap-Up: The HIV Drug Development Pipeline

HIV/AIDS TREATMENT STRATEGIES: CROI 2010 Wrap-Up: The Evolution of Antiretroviral Therapy

DRUGS IN DEVELOPMENT: The End of HIV Drug Development as We Know It?

HIV TREATMENT & HEALTH ISSUES: Whatever Happened to H1N1 (Swine Flu) and HIV? New Answers at CROI 2010

COMPLICATIONS & COINFECTIONS: HIV Independently, but Modestly, Increases Risk of Fragility Fractures, Study of U.S. Male Veterans Finds

More from CROI 2010 >>

 


IAS 2009

HIV/AIDS TREATMENT STRATEGIES: Joel Gallant, M.D., M.P.H., Discusses Clinical Highlights

HIV/AIDS TREATMENT STRATEGIES: Inflammation and HIV: A New Paradigm

DEVELOPING WORLD: How Will Barack Obama Change the Global (and Domestic) Fight Against HIV?

HIV PREVENTION & TRANSMISSION: Revisiting Priorities in the Prevention of Mother-to-Child HIV Transmission

HIV/AIDS TREATMENT STRATEGIES: African Americans, Women Have Lower Virologic Response Rates in Both Arms of Head-to-Head Antiretroviral Trial

More from IAS 2009 >>

 ICAAC 2009

HIV/AIDS TREATMENT STRATEGIES: In the MERIT Trial, Maraviroc Decreased Levels of Immune Activation Earlier Than Efavirenz

HIV/AIDS & RACE/GENDER: Virologic Suppression Is Less Likely Among Antiretroviral-Experienced Black Women. But Why?

HIV PREVENTION & TRANSMISSION: The Evolution of HIV Testing in the U.S.: Are We at the Cusp of a New Era?

HIV/AIDS TREATMENT STRATEGIES: Raltegravir Exhibits More Lipid-Friendly Profile Than Efavirenz, STARTMRK Subanalysis

DRUGS IN DEVELOPMENT: Vicriviroc Safe and Effective in Treatment-Experienced HIV-Infected Patients at 96 Weeks

More from ICAAC 2009 >>

 


CROI 2009

COMPLICATIONS & COINFECTIONS: HPV, Anal Cancer and Cervical Cancer: An Update on Pathogenesis, Treatment and Prevention

ANTIRETROVIRAL THERAPY: Ever Upward: "When to Start" Debate Turns to CD4 Count of 500

COMPLICATIONS & COINFECTIONS: HIV on Par With Smoking, Diabetes as Risk Factor for Atherosclerosis, Large Study Finds

COMPLICATIONS & COINFECTIONS: Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals

ANTIRETROVIRAL THERAPY: The Next Generation of Boosters: Promising Data on Potential Alternatives to Ritonavir

More from CROI 2009 >>


FEATURED INTERVIEWS
Joel Gallant, M.D., M.P.H. Tune in as Joel Gallant, M.D., M.P.H., walks us through some of the most important findings in HIV treatment strategies presented at the 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2009).

(44 min.)
or read transcript

Kimberly Smith, M.D., M.P.H. In a head-to-head antiretroviral trial, Kimberly Smith, M.D., M.P.H., et al find that race and gender may be more critical factors in antiretroviral efficacy than many had long believed.

(5 min.)
or read transcript

For additional podcasts and transcripts from IAS 2009, click here.

PAST CONFERENCES


Advertisement